Key clinical point: Sacubitril/valsartan resulted in reverse cardiac remodeling in patients with type 2 diabetes.
Major finding: Left-ventricle ejection fraction improved 8.7 percentage points in patients with T2DM.
Study details: Post hoc analysis of 361 patients with T2DM enrolled in the PROVE-HF trial investigating sac/val therapy for heart failure.
Disclosures: Lead author Muhammad Shahzeb Khan, MD, MSc, has no relevant financial relationships to disclose. Corresponding author Javed Butler, MD, MPH, MBA disclosed financial relationships with Abbott, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, CVRx, Eli Lilly, G3 Pharmaceutical, Impulse Dynamics, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Sequana, StealthPeptide and Vifor.
Kahn MS et al. JACC: HF. 2020 Dec 9. doi: 10.1016/j.jchf.2020.09.014.